Quintiles Transitional Holdings Inc. (Q) Upgraded by Zacks Investment Research to “Buy”
Quintiles Transitional Holdings Inc. (NYSE:Q) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The brokerage currently has a $107.00 price target on the medical research company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 11.23% from the company’s previous close.
According to Zacks, “Quintiles Transnational Holdings Inc. provides professional services, information and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries. The Company has two segments: Product Development and Integrated Healthcare Services. It offers project management, clinical monitoring services, strategic planning and design services, consulting services contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, brand and scientific communication, and medical education services; outcome/observational services. The Company operates in Americas, Europe and Africa, and the Asia-Pacific. Quintiles Transnational Holdings Inc. is based in Durham, North Carolina. “
Q has been the subject of several other reports. BidaskClub lowered Quintiles Transitional Holdings from a “strong-buy” rating to a “buy” rating in a report on Friday, August 11th. Jefferies Group LLC reissued a “hold” rating and set a $94.00 price objective on shares of Quintiles Transitional Holdings in a report on Friday, August 4th. Robert W. Baird reissued a “hold” rating and set a $98.00 price objective on shares of Quintiles Transitional Holdings in a report on Monday. Citigroup Inc. increased their price objective on Quintiles Transitional Holdings from $96.00 to $97.00 and gave the company a “neutral” rating in a report on Monday, August 7th. Finally, William Blair raised Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $70.10 to $93.42 in a report on Friday, August 4th. Ten investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Quintiles Transitional Holdings presently has a consensus rating of “Buy” and an average price target of $93.61.
Quintiles Transitional Holdings (Q) opened at 96.20 on Wednesday. The stock’s 50 day moving average price is $95.61 and its 200 day moving average price is $88.58. The company has a market capitalization of $20.83 billion, a P/E ratio of 278.84 and a beta of 0.62. Quintiles Transitional Holdings has a 52 week low of $70.10 and a 52 week high of $99.95.
Quintiles Transitional Holdings (NYSE:Q) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $1.09 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.04. The company had revenue of $1.97 billion during the quarter, compared to the consensus estimate of $1.96 billion. Quintiles Transitional Holdings had a return on equity of 14.23% and a net margin of 0.82%. Quintiles Transitional Holdings’s revenue was up 68.7% on a year-over-year basis. During the same period last year, the business posted $0.93 earnings per share. Analysts anticipate that Quintiles Transitional Holdings will post $4.58 earnings per share for the current year.
WARNING: “Quintiles Transitional Holdings Inc. (Q) Upgraded by Zacks Investment Research to “Buy”” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/10/11/quintiles-transitional-holdings-inc-q-upgraded-by-zacks-investment-research-to-buy.html.
In other Quintiles Transitional Holdings news, insider Kevin C. Knightly sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $90.28, for a total transaction of $1,805,600.00. Following the sale, the insider now owns 46,826 shares in the company, valued at $4,227,451.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Cpp Investment Board Private H sold 5,218,245 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $97.33, for a total value of $507,891,785.85. The disclosure for this sale can be found here. Insiders have sold 14,198,382 shares of company stock worth $1,361,834,375 in the last 90 days. Company insiders own 6.40% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Fiduciary Trust Co. purchased a new position in shares of Quintiles Transitional Holdings in the second quarter worth about $105,000. Global X Management Co. LLC increased its holdings in shares of Quintiles Transitional Holdings by 30.8% in the first quarter. Global X Management Co. LLC now owns 1,469 shares of the medical research company’s stock worth $118,000 after buying an additional 346 shares during the period. GWM Advisors LLC purchased a new position in shares of Quintiles Transitional Holdings in the second quarter worth about $122,000. Korea Investment CORP increased its holdings in shares of Quintiles Transitional Holdings by 142.5% in the second quarter. Korea Investment CORP now owns 1,370 shares of the medical research company’s stock worth $123,000 after buying an additional 805 shares during the period. Finally, Archford Capital Strategies LLC purchased a new position in shares of Quintiles Transitional Holdings in the first quarter worth about $160,000. Hedge funds and other institutional investors own 93.21% of the company’s stock.
About Quintiles Transitional Holdings
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.